The U.S. Food and Drug Administration (FDA) has issued an updated warning on diabetes drugs containing the ingredients Saxagliptin and Alogliptin. Drugs with these ingredients include those under the brand names Onglyza, Kombiglyze XR, Nesina, Kazano, and Oseni. The FDA has taken a good look at these drugs and determined that they put users at a risk of heart failure. This is especially true for patients who have heart or kidney disease when they start taking the subject diabetes drugs. Because of these risks, warnings of such are being required for the drug labels, but the drugs have not been recalled.
The recommendation for now is that individuals with type 2 diabetes, who take these drugs to lower blood sugar, consult with their medical providers about whether they should discontinue these particular drugs and be prescribed something different.
If you or a loved one has suffered the adverse impact of any of the type 2 diabetes drugs containing Saxagliptin or Alogliptin, contact your medical provider immediately, and do not hesitate to contact Inserra & Kelley Law Offices for assistance and to see whether you may be entitled to compensation for drug related injury.